• Avaxia leads the field
    of gut-targeted
    antibody therapeutics

Our Company

Avaxia is a clinical-stage biotechnology company focused on gut-targeted antibody therapeutics for gastroenterology diseases. Gut-targeted antibody therapeutics are orally administered, minimally absorbed drugs that act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. In contrast, conventional antibody therapeutics are injected or infused into the bloodstream and distribute throughout the body. Avaxia believes that local treatment of GI diseases at their source with gut-targeted antibodies has the potential to minimize side effects that often occur with parenteral antibodies. Avaxia intends to develop and market our drugs for orphan diseases, especially pediatric indications, while partnering for the larger adult market.


AVX-470, our first gut-targeted antibody therapeutic, is currently in clinical development for inflammatory bowel disease (IBD). The antibody binds TNF, an inflammatory protein. Marketed anti-TNF drugs, such as Remicade® (infliximab), have proven to be highly effective for the treatment of IBD, including ulcerative colitis and Crohn’s disease. However, these anti-TNF drugs have rare but serious side effects, such as risk of serious infection, because they dampen the immune system throughout the body. AVX-470 is intended to act only locally in the intestines where the disease occurs, potentially treating IBD without these rare but serious side effects. Avaxia believes that AVX-470 would meet important unmet medical needs for IBD.